| Assessment Status | NCPE Assessment Process complete |
| HTA ID | - |
| Drug | Certolizumab pegol |
| Brand | Cimzia® |
| Indication | For the treatment of moderate to severe rheumatoid arthritis. |
| Assessment Process | |
| Full submission received from Applicant | 13/03/2010 |
| NCPE assessment completed | 02/09/2010 |
| NCPE assessment outcome | Reimbursement not Recommended. |
The review group did not consider certolizumab cost-effective at the submitted price in September 2010.
The HSE has approved reimbursement following confidential price negotiations.